We are a Swiss law firm, dedicated to providing legal solutions to business, tax and regulatory matters.
SWISS LAW AND TAX
Services
Intellectual Property
Life Sciences, Pharma, Biotech
Litigation and Arbitration
Meet our team
Our knowledge, expertise & publications
View all
Events
Blog
In the VISCHER Innovation Lab, we not only work in the field of law, we also develop our solutions ourselves as far as possible from a technical point of view.
VISCHER Legal Innovation Lab
Red Ink
Careers
Categories: Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk, Blog
Developing a product or service and scaling a startup's business model need big amounts of cash. Thus, most startups seek capital from investors at some point. There are some legal hurdles to overcome when asking people to invest in your startup.
Categories: China Desk, Corporate and commercial, Life Sciences, Pharma, Biotech
The conflict between the USA and China continues to escalate and will probably also have an impact on the biotechnology sector.
Categories: Intellectual Property, Life Sciences, Pharma, Biotech, Litigation and Arbitration, Blog
Pharmaceutical contract manufacturers are exposed to the risk of being sued by patent owners. We explain how they can protect themselves from such lawsuits.
Category: Life Sciences, Pharma, Biotech
The liberalization of Swiss narcotics legislation now allows for easier access to and trade in Medical Cannabis. Dan Pruschy and Stefan Kohler give an overview.
Categories: Life Sciences, Pharma, Biotech, Startup Desk
In the world of startup financing, a convertible note is an instrument offering several advantages for a startup seeking to raise funds in Switzerland.
The new provisions on integrity and transparency in the therapeutic products sector have applied since 1.1.2020. Nevertheless, misinterpretations often occur.
The management of clinical trials faces major challenges due to COVID-19.
EU Commission proposes postponement of MDR start date.
On 26 May 2020, the new EU Medical Device Regulation becomes effective. Swiss medical device manufacturers should adapt to the new rules in good time.
Categories: China Desk, Life Sciences, Pharma, Biotech
On December 1, 2019, China introduces the drug marketing license holder (MAH) system nationwide. New opportunities for Pharma and Biotech to come.
Displaying results 1 to 10 out of 11
Das ist unsere englische Blogseite, unsere Blogartikel sind hier auch auf Deutsch verfügbar.
